Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 8/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.53 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6330488 | 0.93 | NOS2 (0.52) | NOS2CYP2D6SLC6A2SLC6A4BCL2A1 | |
| Oxalic Acid SCHEMBL6337687 | 0.92 | NOS2 (0.55) | NOS2CYP2D6SLC6A2SLC6A4BCL2A1 | |
| SCHEMBL6327847 | 0.87 | NOS2 (0.49) | NOS2CYP2D6SLC6A2SLC6A4BCL2A1 | |
| SCHEMBL6337815 | 0.85 | NOS2 (0.61) | NOS2CYP2D6SLC6A2SLC6A4MRGPRX4 | |
| SCHEMBL6328415 | 0.84 | CYP2D6 (0.52) | NOS2CYP2D6SLC6A2SLC6A4BCL2A1 | |
| SCHEMBL6330654 | 0.83 | NOS2 (0.53) | NOS2CYP2D6SLC6A2SLC6A4BCL2A1 | |
| SCHEMBL6328357 | 0.81 | CYP2D6 (0.48) | NOS2CYP2D6SLC6A2SLC6A4BCL2A1 | |
| SCHEMBL6328431 | 0.80 | NOS2 (0.49) | NOS2CYP2D6SLC6A2SLC6A4BCL2A1 | |
| Oxalic Acid SCHEMBL6337578 | 0.79 | CYP2D6 (0.53) | NOS2CYP2D6SLC6A2SLC6A4BCL2A1 | |
| SCHEMBL6329018 | 0.78 | SLC6A4 (0.70) | NOS2CYP2D6SLC6A2SLC6A4BCL2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900243-B2 | Phenylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2005-05-31 | — | — | US | disclosed |
| EP-1263715-B1 | NOVEL PHENYLHETEROALKYLAMINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| US-20030065174-A1 | Novel phenylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2003-04-03 | — | — | US | disclosed |
| EP-1263715-A1 | NOVEL PHENYLHETEROALKYLAMINE DERIVATIVES | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001062714-A1 | NOVEL PHENYLHETEROALKYLAMINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065174-A1 | Novel phenylheteroalkylamine derivatives | OPRK1, NOS2, OPRM1 | NOS2 2/4885CYP2D6 59/4885SLC6A2 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.